Advanced systemic mastocytosis with strong expression of signaling lymphocyte activation marker family member 7 (SLAMF7) responsive to therapy with elotuzumab and lenalidomide

Leuk Lymphoma. 2020 Feb;61(2):485-487. doi: 10.1080/10428194.2019.1668939. Epub 2019 Sep 30.

Authors

Ahmet H Elmaagacli¹, Christian Jehn¹, Yana Shikova¹, Michael Huber², Hans Salwender¹, Farouk Dahmash¹, Anju Singh¹, Cornelius Niggemann³, Mathias Vierbuchen³

Affiliations

¹ Department of Hematology/Oncology and Stem Cell Transplantation, Asklepios Klinik St. Georg, Hamburg, Germany.
² Institute of Biochemistry and Molecular Immunology, Medical Faculty, RWTH Aachen University, Aachen, Germany.
³ Department of Pathology, Asklepios Klinik St. Georg, Hamburg, Germany.

PMID: 31566043
DOI: 10.1080/10428194.2019.1668939

No abstract available

Publication types

Letter

MeSH terms

Antibodies, Monoclonal, Humanized
Family
Humans
Lenalidomide
Lymphocyte Activation
Mastocytosis, Systemic* / diagnosis
Mastocytosis, Systemic* / drug therapy
Mastocytosis, Systemic* / genetics
Multiple Myeloma*
Signaling Lymphocytic Activation Molecule Family

Substances

Antibodies, Monoclonal, Humanized
SLAMF7 protein, human
Signaling Lymphocytic Activation Molecule Family
elotuzumab
Lenalidomide